比美吉珠单抗治疗银屑病关节炎3年安全性和疗效:两项3期研究结果
本报告基于BE OPTIMAL和BE COMPLETE两项3期研究及其开放扩展研究,评估比美吉珠单抗皮下注射160mg每4周治疗银屑病关节炎患者至3年的安全性和疗效。结果显示,bDMARD初治和TNFi-IR患者中疗效应答持续至3年,安全性特征与第1年一致,未发现新的安全信号。
要点
- bDMARD初治和TNFi-IR患者中比美吉珠单抗疗效应答持续至3年。
- 安全性特征与第1年一致,未发现新的安全信号。
- 支持比美吉珠单抗作为银屑病关节炎的长期治疗选择。
核心结论
- 比美吉珠单抗在bDMARD初治和TNFi-IR银屑病关节炎患者中显示出持续至3年的高水平和良好耐受性。
研究设计与样本
- BE OPTIMAL(bDMARD初治)和BE COMPLETE(TNFi-IR)两项3期研究,评估皮下比美吉珠单抗160mg每4周,完成者可进入BE VITAL开放扩展研究。
主要发现
- 截至3年,bDMARD初治/TNFi-IR患者中分别有546/299(76.7%/74.8%)完成第3年。
- bDMARD初治患者治疗中出现的不良事件暴露调整发生率(每100患者年)为164.2(95%CI 152.7-176.3),TNFi-IR患者为88.6(95%CI 79.1-98.9)。
- 第1年和第3年时,bDMARD初治/TNFi-IR患者分别有56.1%/50.4%和53.2%/55.2%达到ACR50。
- 第1年和第3年时,bDMARD初治/TNFi-IR患者分别有61.8%/58.2%和59.5%/59.1%达到肿胀关节数消退。
- 第1年和第3年时,bDMARD初治/TNFi-IR患者分别有64.7%/66.2%和61.9%/67.5%达到PASI 100应答。
关键数值与推荐
- ACR50应答率:第1年bDMARD初治56.1%、TNFi-IR 50.4%;第3年bDMARD初治53.2%、TNFi-IR 55.2%。
- 肿胀关节数消退率:第1年bDMARD初治61.8%、TNFi-IR 58.2%;第3年bDMARD初治59.5%、TNFi-IR 59.1%。
- PASI 100应答率:第1年bDMARD初治64.7%、TNFi-IR 66.2%;第3年bDMARD初治61.9%、TNFi-IR 67.5%。
临床怎么用
- 对于bDMARD初治和TNFi-IR的银屑病关节炎患者,比美吉珠单抗可作为长期治疗选择,疗效维持至3年且安全性可控。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has demonstrated tolerability and clinical efficacy in patients with PsA. Here, we report an additional year of safety and efficacy of bimekizumab treatment to 3 years. METHODS: BE OPTIMAL [NCT03895203; biologic DMARD (bDMARD)-naïve] and BE COMPLETE [NCT03896581; prior inadequate response/intolerance to TNF inhibitors (TNFi-IR)] assessed s.c. bimekizumab 160 mg every 4 weeks in patients with PsA. Study completers could enrol in the BE VITAL open-label extension (NCT04009499). Outcomes were reported as observed, or using modified non-responder or multiple imputation, to 3 years. RESULTS: Overall, 546/299 (76.7/74.8%) bDMARD-naïve/TNFi-IR patients randomized to bimekizumab or placebo at baseline (Bimekizumab Total group) completed year 3. Treatment-emergent adverse event rates [exposure-adjusted incidence rate/100 patient-years (95% CI)] for bimekizumab-treated patients through 3 years were 164.2 (152.7-176.3) in bDMARD-naïve and 88.6 (79.1-98.9) in TNFi-IR patients, consistent with those at year 1 with no new safety signals identified. Response rates for efficacy outcomes were sustained up to 3 years; at year 1 and year 3, respectively, 56.1/50.4% and 53.2/55.2% of bDMARD-naïve/TNFi-IR patients achieved ACR50, 61.8/58.2% and 59.5/59.1% achieved swollen joint count resolution, and 64.7/66.2% and 61.9/67.5% had 100% improvement from baseline in Psoriasis Area and Severity Index. Responses for other efficacy measures were similarly sustained and consistent in bDMARD-naïve and TNFi-IR patients. CONCLUSION: Bimekizumab demonstrated sustained high levels of efficacy and tolerability to 3 years, supporting its suitability for long-term treatment in bDMARD-naïve and TNFi-IR patients with PsA. TRIAL REGISTRATION: BE OPTIMAL: NCT03895203; BE COMPLETE: NCT03896581; BE VITAL: NCT04009499.
引用
- Gossec L, Coates LC, Landewé RBM, et al. Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies. Rheumatology (Oxford). 2026. PMID: 41838419. doi:10.1093/rheumatology/keag118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。